IDENTIFICATION & CHARACTERISATION OF MOLECULAR DRIVERS OF THERAPEUTIC RESISTANCE
With
Professor Pieter Eichhorn
Group Leader, Curtin Medical Research Institute &
Dean of Research Infrastructure & Professor at Curtin University
Western Australia
RESEARCHER PROFILE
Filmed in Perth, Western Australia | February 2026
Professor Pieter Eichhorn is an internationally experienced cancer biologist and research leader whose career has been defined by high-impact contributions at the interface of functional genomics, translational oncology, and research infrastructure strategy.
He completed his PhD at the University of Newcastle upon Tyne, contributing to the cloning of the gene associated with Cornelia de Lange Syndrome, before undertaking postdoctoral training at the Netherlands Cancer Institute in the laboratory of René Bernards. There, he performed pioneering functional genetic screens that identified key regulators of oncogenesis and therapy resistance, including critical roles for the PI3K signalling pathway in resistance to targeted breast cancer therapies.
He subsequently worked Dr. Jose Baselga at the Vall d’Hebron Institute of Oncology and Harvard Medical School contributing to studies on signalling networks, resistance mechanisms, and ubiquitin pathway regulation in cancer.
A major career highlight has been the identification and characterisation of molecular drivers of therapeutic resistance, including work on PI3K pathway biology and ubiquitin-regulated oncogenic signalling, published in high-impact journals and informing biomarker-driven therapeutic strategies.
At Curtin University, he has established and led a multidisciplinary translational research program focused on deubiquitinases, epithelial plasticity, and non-coding RNA biology in breast and melanoma. In parallel, he has provided strategic leadership as Dean of Research Infrastructure, overseeing major national and institutional infrastructure investments, NCRIS-aligned initiatives, and large-scale collaborative platforms that enhance research capability and clinical translation.
COLLABORATIONS
National University of Singapore, Walter and Eliza Hall Institute, Peter Mac, Vall d’Hebron, Helmholtz Munich, University of Manchester,
FUNDING
World Cancer Research Fund, Cancer Council Wa, Australia Center for RNA Therapy in Cancer
Source: Supplied
https://orcid.org/0000-0001-5840-943X
-
Novel immunotherapies in lymphoma
Dr Sean Harrop is a dual-trained haematologist having completed his clinical and laboratory haematology training at the Peter MacCallum Cancer Centre, Royal Melbourne Hospital and St Vincent’s Hospital Melbourne. He is the current clinical haematology fellow (aggressive lymphoma) at Peter MacCallum and a PhD student in the Cancer Immunology Program in the Neeson Lab.
-
Lasers, microbiology and dental materials in clinical dental practice
Professor Laurence Walsh AO is an Emeritus Professor at the University of Queensland, holding an adjunct title at Griffith University and a part-time position as the Chief Dental Officer at Dentroid, which is based in Canberra. In addition to these roles, he serves on several committees of the Dental Association and is the current president of the Australian Society for Laser Dentistry.
-
Treatment pathways for chronic plantar heel pain
Jason Rogers is a Tasmanian physiotherapist clinician-researcher with a longstanding interest in improving musculoskeletal foot and ankle conditions. He completed his PhD at the Menzies Institute for Medical Research at the University of Tasmania in 2022 investigating the clinical and imaging factors associated with a common foot complaint known as chronic plantar heel pain.
